molecules of the month


mutant + WT CFTR Cl channel potentiator

oral 300 mg BID , Ph. II in COPD and CF

from 1M cmpd cell-based HTS + opt.

J. Med. Chem., May 24, 2021

Millenium/Takeda, Cambridge, MA

2 mins read

The Novartis mutant and WT CFTR potentiator, icenticaftor (QBW251), is an oral Ph. II clinical candidate for chronic obstructive pulmonary disease (COPD), which is anticipated to become the 3rd leading cause of death globally. The compound had positive proof of concept studies in both cystic fibrosis and COPD, and the advancement of a WT CFTR modulator into the large COPD indication is a significant development. Since there are not good PK/PD models for cystic fibrosis, the candidate was nominated based on in vitro properties and safety studies, but has shown target engagement in humans via biomarkers such as sweat chloride. This is a great medicinal chemistry case study as the starting point for icenticaftor was objectively unattractive, with furan, aniline, and ester…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: